


ZD4054

ENTHUSE MO

In non-metastatic, castrate-resistant prostate cancer

A Phase III randomized, double-blinded, multicenter study in patients with non-metastatic, castrate-resistant prostate cancer with rising serum prostate-specific antigen (PSA) levels despite medical or surgical castration



Purpose: To assess the efficacy and safety of ZD4054 in improving overall survival and progression-free survival

Primary endpoint: Overall survival and progression-free survival

Secondary endpoints: Safety and tolerability, PSA progression, quality of life, symptomatic progression

Participating countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Czech Republic | Denmark | Finland | France | Germany | Hungary | India | Israel | Italy | Japan | Republic of Korea | Latvia | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russian Federation | Serbia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

ZD4054 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.

For more information,
please contact:

Cancer Study Locator service, sponsored by
AstraZeneca at 1-877-400-4656
Or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov

AstraZeneca 

AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware
www.astrazeneca.com